What changed: Nasopharyngeal carcinoma
Every dated change on the records linked to Nasopharyngeal carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2025 · 2
October 2023 · 1
2023 · 2
2021 · 3
- 2021ApprovalPenpulimabPenpulimab approved in CN
Relapsed/refractory classical Hodgkin lymphoma; later NPC, NSCLC
- 2021GuidelineNasopharyngeal carcinomaGuideline CSCO/ASCO NPC guideline 2021: Stage II-IVA
Induction gemcitabine-cisplatin ×3 then concurrent cisplatin-IMRT (for stage III-IVA); concurrent chemoradiation alone for stage II; adjuvant capecitabine for high-risk (detectable post-RT EBV DNA, N2-3). (NCCN Category 1 (induction GP), ESMO-MCBS A)
- 2021MilestoneToripalimabJUPITER-02, CAPTAIN-1st, RATIONALE-309: PD-1 + GP first line
A milestone in how this cancer is treated.
2019 · 3
- 2019ApprovalCamrelizumabCamrelizumab approved in China
Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal
- 2019ApprovalTislelizumabTislelizumab approved in China
Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal
- 2019MilestoneGemcitabine + cisplatinInduction gemcitabine-cisplatin improves survival (Zhang, NEJM)
A milestone in how this cancer is treated.